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Abstract: Electronegative low-density lipoprotein (LDL(−)) is a minor LDL subfraction that is present
in blood with inflammatory and apoptotic effects. We aimed to evaluate the role of sphingolipids
ceramide (Cer), sphingosine (Sph), and sphingosine-1-phosphate (S1P) in the LDL(−)-induced
effect on monocytes. Total LDL was subfractioned into native LDL and LDL(−) by anion-exchange
chromatography and their sphingolipid content evaluated by mass spectrometry. LDL subfractions
were incubated with monocytes in the presence or absence of enzyme inhibitors: chlorpromazine
(CPZ), d-erythro-2-(N-myristoyl amino)-1-phenyl-1-propanol (MAPP), and N,N-dimethylsphingosine
(DMS), which inhibit Cer, Sph, and S1P generation, respectively. After incubation, we evaluated
cytokine release by enzyme-linked immunosorbent assay (ELISA) and apoptosis by flow cytometry.
LDL(−) had an increased content in Cer and Sph compared to LDL(+). LDL(−)-induced cytokine
release from cultured monocytes was inhibited by CPZ and MAPP, whereas DMS had no effect.
LDL(−) promoted monocyte apoptosis, which was inhibited by CPZ, but increased with the addition
of DMS. LDL enriched with Sph increased cytokine release in monocytes, and when enriched with Cer,
reproduced both the apoptotic and inflammatory effects of LDL(−). These observations indicate that
Cer content contributes to the inflammatory and apoptotic effects of LDL(−) on monocytes, whereas
Sph plays a more important role in LDL(−)-induced inflammation, and S1P counteracts apoptosis.
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1. Introduction
Sphingolipids have an essential structural function in cell membranes. In addition, these lipid
metabolites are emerging as important intracellular and intercellular signaling molecules that are
involved in the progress of inflammatory diseases and atherosclerosis [1]. These bioactive lipids are
present in atherosclerostic plaque, where they play inflammatory and apoptotic roles [2]. Sphingolipid
metabolism is complex and highly interconnected, and each step is controlled by specific enzymes.
The core component of sphingolipid metabolism is ceramide (Cer), which is generated by the hydrolysis
of sphingomyelin (SM) by sphingomyelinase activity (SMase), and can be hydrolyzed by ceramidase
(CDase) activity, yielding sphingosine (Sph). Sph can subsequently be phosphorylated by S1P kinase
to generate sphingosine-1-phosphate (S1P) [3].
Cer is a widely studied molecule that regulates cell differentiation, inflammation, and apoptosis [4].
Its plasma concentration is elevated in patients who are at high cardiovascular risk [5,6]. The role of
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Sph in atherosclerosis and inflammation is not clearly established, and its biological effects have been
reported to overlap with those promoted by Cer [7]. Sph has been shown to promote inflammatory
response [8] and apoptosis [9], although it has also been reported to induce an anti-apoptotic effect [10].
S1P is a pleiotropic bioactive metabolite, and is an important intercellular signaling molecule recognized
by specific cell receptors whose subtype determines the effect on cells [11]. S1P is reported to promote cell
proliferation, survival, and migration [12–14]. Regarding inflammation, some studies have described
how it promotes inflammation [15–17], whereas others have reported an anti-inflammatory action,
mainly when it is bound to its major carrier, high-density lipoprotein (HDL) [18–20]. Although LDL
may contain low quantities of S1P, it mainly carries Cer and Sph [21]. Some studies have shown that
LDL with an increased Cer content induces inflammation [22,23], whereas the effect of an increased
content of Sph and S1P in LDL is unknown.
Electronegative low-density lipoprotein (LDL(−)) is a minor LDL subfraction found in blood
circulation that has various atherogenic effects, such as the induction of inflammation in cultured cells.
It differs from native LDL (LDL(+)) in several physicochemical properties [24], including the presence
of phospholipolytic activities. Indeed, LDL(−) has a fivefold to sixfold increased concentration of the
enzyme platelet-activating factor acetylhydrolase (PAF-AH) compared with LDL(+) [25]. In addition,
a phospholipase C (PLC)-like activity is believed to be associated with LDL(–), having a high avidity
to degrade lysophosphatidylcholine (LPC) by lysoPLC activity and sphingomyelin (SM) by SMase
activity [26]. These enzymatic activities seem to be involved in the increased concentrations in LDL(−)
of Cer and non-esterified fatty acid (NEFA), which are responsible for LDL(–)-induced cytokine release
in monocytes [22,27,28]. However, other compounds, such as those resulting from Cer hydrolysis—Sph
and S1P—could also be increased in LDL(−) and be involved, not only in the inflammatory effect of
LDL(–), but also in a putative apoptotic effect on monocytes.
LDL(−) exerts an apoptotic effect in macrophages [29] and in endothelial cells [30], being
attributed in the latter to the increased Cer content in LDL(−) [30]. In fact, Cer and NEFA are inductors
of apoptosis [31,32], and an increased content of these molecules confers apoptotic properties on
LDL [31,33,34]. Moreover, modified LDL can promote apoptosis by increasing the Cer content in
cells [31,35].
In the current study, we sought to determine the specific involvement of the sphingolipids Cer,
Sph, and S1P in the inflammatory and apoptotic effects of LDL(−) in human monocytes isolated from
plasma. For this purpose, we used specific inhibitors of SMase, CDase, and Sph kinase activities,
as summarized in the Methods section.
2. Material and Methods
2.1. LDL Isolation and Modification
Plasma samples from healthy normolipemic subjects (total cholesterol <5.2 mmol/L, triglyceride
<1 mmol/L) were obtained in EDTA-containing Vacutainer tubes. All the subjects gave their
written informed consent, and the study was conducted after approval from the Institutional
Ethics Committee of the Hospital Sant Pau (IIBSP-APO-2013-105, 25 February 2015). All the LDL
preparations were performed in conditions that prevented oxidation and endotoxin contamination [36].
LDL (1.019–1.050 kg/L) was isolated from plasma by sequential flotation ultracentrifugation at 4 ◦C. In
some experiments, LDL was modified by different treatments: by incubation with SMase (10 U/g apoB)
for 2 h at 37 ◦C to increase its Cer concentration (SMase-LDL); by incubation with NEFA (NEFA-LDL) [28];
and by incubation with Sph-enriched liposomes (10 µM) (Sph-LDL), as described for Cer-enriched
liposomes [22]. The enrichment in these compounds was assessed by thin-layer chromatography, and
the aggregation level of modified LDL was evaluated by gradient gel electrophoresis, as previously
described [22].
Total LDL was fractionated in LDL(+) and LDL(−) by preparative anion-exchange chromatography
in an ÄKTA-FPLC system (GE Healthcare) [37]. LDL fractions were concentrated with Amicon
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centrifugal filters (Merck Millipore). LDL(+) and LDL(−) compositions were determined in a Cobas®
501 autoanalyzer, including total cholesterol, triglyceride, apoB (Roche, Basel, Switzerland), NEFA,
and phospholipid (Wako, Neuss, Germany).
2.2. Lipidomic Analysis
Baseline levels of sphingolipids in LDL(+) and LDL(−) were evaluated by liquid chromatography-
mass spectrometry (LC-SM) in the CIBERDEM-Metabolomics Platform of Universitat Rovira i Virgili.
First, a lipid extraction of LDL samples (32 µg apoB) was performed. LDLs were lyophilized and
resuspended in 220 µL of methanol (MeOH) followed by vortexing. Then, 440 µL of dichloromethane
were added followed by vortexing. Afterwards, 140 µL of ultrapure water was added, vortexed, and
stored at room temperature for 20 min. The solution was centrifuged for 10 min at 14,500 rpm (4
◦C). Next, 400 µL of the organic phase was collected and evaporated to dryness with N2. Samples
were reconstituted in 150 µL of MeOH:toluene (9:1) and transferred to LC-MS vials. Lipid extracts
(5µL) were injected in a Ultra High Perfomance Liquid Chromatography system (1290 Agilent, Santa
Clara, CA, USA) coupled to a triple quadrupole (QqQ) mass spectrometer (6490 Agilent Technologies)
operated in positive electrospray ionization (ESI+) mode. The instrument was set to acquire in multiple
reaction monitoring mode. Lipids were separated using C18-RP (ACQUITY UPLC BEH 2.1 × 150 mm,
1.7µm, Waters) chromatography at 65 ◦C and at a flow rate of 0.4 mL/min. The solvent system was
A = acetonitrile:water (60:40) in 10 mM of ammonium formate, and B = isopropanol:acetonitrile (90:10)
in 10 mM of ammonium formate. The gradient elution started at 15% B and went to 30% from minute
0 to 2, 48% B from minute 2 to 2.5, 82% B from minute 2.5 to 11, and 99% B from minute 11 to 11.5.
Quality control samples (QC) consisting of pooled samples were injected before the first study sample
and then periodically after four study samples.
Cer 14:0, Cer 16:0, Cer 18:0, Cer 20:0, Cer 22:0, Cer 24:0, Sph 18:1, and S1P 18:1 relative concentrations
were analyzed by this method. Total Cer was considered to be the sum of all the Cer species evaluated.
2.3. Inflammatory Action on Monocytes
Peripheral blood from volunteers was collected, and mononuclear cells were isolated by density
gradient centrifugation using a density solution of 1.077 kg/L (Lympholyte Cedarlane) [37]. Cells
were seeded on 12-well plates (2 × 106 cells/mL), and monocytes were separated from lymphocytes
according to their adhesive properties. All the subjects gave their written informed consent, and the
study was conducted after approval from the Institutional Ethics Committee of the Hospital Sant Pau.
To evaluate the role of sphingolipids in the inflammatory and apoptotic effects of LDL(−),
several inhibitors were tested: chlorpromazine (CPZ) (Sigma) is an inhibitor of SMase
activity; d-erythro-2-(N-myristoyl amino)-1-phenyl-1-propanol (MAPP) (Cayman) is an inhibitor
of neutral/alkaline CDase activity; and N,N-dimethylsphingosine (DMS) (Cayman) is an inhibitor of
Sph kinase. The effect of these inhibitors is summarized in Table 1.
Table 1. Inhibitors used in the study.
Inhibitor Abbreviation Enzyme Substrate Product
Chlorpromazine CPZ SMase SM Cer andphosphorylcholine
d-erythro-2-(N-myristoyl
amino)-1-phenyl-1-propanol MAPP CDase Cer Sph and NEFA
N,N-dimethylsphingosine DMS Sph kinase Sph S1P
All the inhibitors were used at 10 µM. LDL(+) and LDL(−) were incubated in the presence or
absence of these inhibitors for 20 h; afterwards, they were dialyzed against RPMI 1640 medium
(supplemented with 1% fetal calf serum, 2 mM of L-glutamine, 0.1 U/L of streptomycin, and 0.1 U/L
of penicillin), and filtered in sterile conditions. Then, monocytes were incubated for 20 h with
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these LDL subfractions (60 mg apoB/L) (pre-incubation conditions). Monocytes were also incubated
simultaneously with inhibitors plus LDL(+) or LDL(−) (60 mg apoB/L) (co-incubation), and without
LDL (blank or basal condition) in the presence or absence of inhibitors. All the incubations were
performed in the above-mentioned RPMI 1640 medium. Cell supernatants were collected after 20 h
to evaluate the release of IL1β, IL6, IL10, and MCP1, using ELISA kits (eBioscience for all, except
Diaclone for IL1β), as described [38], and following the manufacturer’s recommendations. Moreover,
monocytes were collected to analyze apoptosis by flow cytometry.
2.4. Apoptosis Assay
Apoptosis assays were performed in monocytes incubated with LDL(−) plus MAPP or DMS,
and with LDL(−) pre-incubated with CPZ (all inhibitors at 10 µM). Apoptosis was determined by
an Annexin V-FITC, Apoptosis detection kit (eBioscience-Invitrogen, Carlsbad, CA, USA). Briefly,
monocytes were collected and resuspended in 200 µL of binding buffer (200,000 cells). Cell suspension
was stained with Annexin V-FITC, which binds to phosphatidylserine, for 10 min in darkness at room
temperature. Afterwards, cells were washed and resuspended in 190 µL of binding buffer. After the
addition of 10 µL of propidium iodide (PI), the fluorescence on stained cells was measured by flow
cytometry in a MACSQuant® Analyzer MQ10 (Milteny Biotech GmbH, Bergisch Gladbach, Germany)
and analyzed using MACSQuant software (Milteny Biotech GmbH). Non-stained cells (A-PI-) were
considered to be viable cells, A+PI- was considered to indicate early apoptosis, double staining (A+PI+)
was considered to indicate late apoptosis, and A-PI+ was considered to indicate necrotic cells. Total
apoptosis is the sum of early and late apoptosis.
2.5. Statistical Analyses
Differences between groups were tested using the Wilcoxon signed-rank test for paired data.
Results were expressed as mean ± SD. A value of p < 0.05 was considered to be statistically significant.
3. Results
3.1. LDL(−) Has an Increased Content in Sph and Cer
We aimed to evaluate the content of Cer, Sph, and S1P in LDL(+) and LDL(−) by mass spectrometry.
Figure 1 shows that LDL(−) had a much higher content in Cer than LDL(+), as previously described
by a less sensitive method [22]. In addition, LDL(−) showed a twofold content in Sph compared to
LDL(+), whereas S1P was undetectable in both LDL subfractions.
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Figure 1. Sphingosine (Sph) and ceramide (Cer) basal content in low-density lipoprotein (LDL)
subfractions. Native LDL(+) (blue bars) and negative LDL(−) (red bars) (32 µg of apolipoprotein B
(apoB) were analyzed by mass spectrometry to evaluate the baseline levels of sphingolipids. Cer includes
all the Cer species that were evaluated. Results are expressed as a relative increase versus LDL(+),
mean ± SD (n = 4), * vs. LDL(+), p < 0.05.
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3.2. Sph and Cer Are Involved in the Cytokine Release Promoted by LDL(−) in Monocytes
The role of Cer, Sph, and S1P in the cytokine release promoted by LDL(−) in monocytes was
evaluated. For this purpose, specific inhibitors involved in the generation of the above-mentioned
sphingolipids were used, respectively: chlorpromazine (CPZ) (SMase inhibitor), d-erythro-2-
(N-myristoyl amino)-1-phenyl-1-propanol (MAPP) (CDase inhibitor), and N,N-dimethylsphingosine
(DMS) (Sph kinase inhibitor).
Inhibitors alone did not modify the release of cytokines compared to basal values in the absence
of LDLs (data not shown).
In the presence of LDL(−), the addition of DMS did not alter the release of monocyte
chemoattractant protein 1 (MCP1) and interleukin (IL)-6 promoted by LDL(−), thereby suggesting that
S1P generation was not involved in the inflammatory action of this lipoprotein (Figure 2). By contrast,
the addition of CPZ inhibited the release of these cytokines induced by LDL(−).
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Finally, the addition of MAPP decreased MCP1 and IL-6 release induced by LDL(−) as well as that
of IL-1β and IL-10, in a concentration-dependent manner (Figure 3). However, the effect promoted
by LDL(+) was not modified by the addition of any inhibitor (in the case of MAPP, inhibition lower
than 5%). Taken together, the results indicate that both Sph and Cer contribute to LDL(−)-induced
inflammation in human monocytes.
To confirm the role of increased Sph and Cer content in LDL on the inflammatory response of
monocytes, we conducted experiments in which LDL(+) was enriched “in vitro” with these compounds
by incubation with liposomes containing Sph or by SMase lipolysis, respectively. Supplementary
Figure S1 shows the enrichment of Sph and Cer in these “in vitro”-modified LDLs and the effect of such
modification in the aggregation of LDL particles. The increase in Sph and Cer was 1.5-fold and sixfold,
respectively, as calculated by densitometry versus unmodified LDL. Figure 4 shows that compared
to unmodified LDL, LDL enriched with Sph (Sph-LDL), and LDL treated with SMase (SMase-LDL)
induced the release of IL-6, as a representative cytokine induced by LDL(−).
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Figure 3. MCP1, IL-1β, IL-6, and IL-10 release pro y LDL(−) in human mon cytes in the
presence or absence of MAPP. Monocytes were incubated with LDL(−) (60 mg apoB/L) in the absence
of MAPP (red bars) or in the presence of MAPP at 5 µM (yellow bars) and 10 µM (light yellow bars).
After 20 hours of incubation, cytokine release was measured by ELISA. Results are expressed as mean
± SD (n = 5), * vs. the absence of inhibitor, p < 0.05.
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Figure 4. IL-6 release promoted by “in vitro” modified LDL. Monocytes were incubated with unmodified
LDL (blue bars) or m dified LDL ( ellow bars), both at 60 mg apoB/L. LDL was m dified by incubation
with Sph-enriched liposomes (at 0 and 10 µM) and by sphingomyelinase (SMase) treatment (at 0 and
10 U enzyme/g apoB). After 20 hours of incubation, cytokine release was measured by ELISA. Results
are expressed as µg/L and as mean ± SD (n = 6), * vs. unmodified LDL, p < 0.05.
Next, we sought to determine whether the inhibition induced by MAPP and CPZ on cytokine
release was due to a direct effect on LDL(−) or was a consequence of an effect on cell enzymes. For this
purpose, LDL(−) was pre-incubated with MAPP or CPZ, and then dyalized to remove excess inhibitor
prior to its addi ion to monocytes. T is effect was compared to that promoted when monocytes were
incubated simultaneously with LDL(−) and an inhibitor (co-incubation). Figure 5 shows IL-6 release,
as a representative cytokine induced by LDL(−). No significant difference was observed when using
MAPP between pre-incubati n and co-incubation. By contrast, CPZ exerted a more effective inhibitory
effect in co-incubation tha in pre-incubation conditions. These observations indicat th t CPZ has a
direct ffect on cells, perhaps by inhibiting c ll SMase.
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Figure 5. IL-6 release promoted by LDL(−) in pre-incubation or co-incubation with MAPP and CPZ.
Monocytes were incubated with LDL(−) (60 mg apoB/L), which was pre-incubated (green bars) or
co-incubated (yellow bars) with the inhibitors MAPP and CPZ, both at 10 µM. After 20 h of incubation,
cytokine release was measured by ELISA. Results are expressed as % of inhibition versus LDL(−) in the
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3.3. Cer Is Involved in LDL(−)-Induced Apoptosis
Figure 6 shows that LDL(−) displayed a twofold increase in the total apoptotic effect on monocytes
compared to LDL(+), which did not promote apoptosis. LDL(−) did not induce statistically significant
differences in necrosis compared to LDL and the blank of cells.
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Figure 6. Apoptosis induced by LDL(+) and LDL(−) in human monocytes. (A) Early, late, and total
apoptosis, and necrosis induced in basal conditions (blank) or by LDL(+) (blue bars) and LDL(−)
(red bars) (60 mg apoB/L) were evaluated by flow cytometry. Results are expressed as percentage of
apoptotic cells, mean ± SD (n = 6), * vs. blank cells, and # vs. LDL(+), p < 0.05 (B). Representative
experiment showing the effect of LDL(+) (left panel) and LDL(−) (right panel) on human monocytes.
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The effect of enzyme inhibitors was also assayed in LDL(−)-induced apoptosis. Figure 7 shows
that DMS enhanced the apoptotic effect of LDL(−), whereas CPZ decreased this effect, both in early
and late apoptosis. These observations suggest that Cer is involved in LDL(−)-induced apoptosis,
whereas S1P would tend to counteract this action. On the other hand, the presence of MAPP did not
promote any significant effect, despite a slight tendency to increase late apoptosis.
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Figure 8. Total apoptosis induced by modified LDL(–). Total apoptosis induced by LDL modified by
SMase treatment (yellow bars), Sph (green bars), or non-esterified fatty acid (NEFA) enrichment (blue
bars), as described in the Methods section. Results are expressed as mean ± SD (n = 5), * vs. unmodified
LDL, p < 0.05.
4. Discussion
Sphingolipids and their metabolizing enzymes are described to be involved in atherogenesis.
This study provides a novel contribution to understanding of the role of sphingolipids in inflammation
and apoptosis, particularly focusing on the involvement of these metabolites in the atherogenic effects
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promoted by LDL(−) on monocytes. As determined by lipidomic analysis, LDL(−) had a higher content
in Cer and Sph than LDL(+), and our findings show that the increase in these sphingolipids contributes
to its inflammatory and apoptotic effects. Cer content in LDL(−) contributes to both LDL(–)-induced
inflammatory and apoptotic effects, whereas Sph plays a more important role in its inflammatory effect.
By contrast, S1P counteracts the apoptotic action exerted by LDL(–). These findings are summarized in
Figure 9, which shows the effect of the inhibitors used in the study on sphingolipid generation and the
ensuing LDL(–)-induced inflammatory and apoptotic actions.Biomolecules 2019, 9, x FOR PEER REVIEW 8 of 15 
 
Figure 9. Effect of the inhibitors used in the study on sphingolipid generation and on LDL(−)-induced 
inflammatory and apoptotic actions. CPZ blocks sphingomyelin degradation, thereby decreasing Cer 
content and LDL(−)-induced cytokine release and apoptosis. MAPP blocks Cer degradation, leading 
to a decrease in Sph and NEFA generation, which seems to develop an essential role in inflammation, 
but a likely minor role in apoptosis. DMS blocks sphingosine-1-phosphate (S1P) generation, thus 
leading to an increase in the apoptotic effect of LDL(−). 
3. Discussion 
Sphingolipids and their metabolizing enzymes are described to be involved in atherogenesis. 
This study provides a novel contribution to understanding of the role of sphingolipids in 
inflammation and apoptosis, particularly focusing on the involvement of these metabolites in the 
atherogenic effects promoted by LDL(−) on monocytes. As determined by lipidomic analysis, LDL(−) 
had a higher content in Cer and Sph than LDL(+), and our findings show that the increase in these 
sphingolipids contributes to its inflammatory and apoptotic effects. Cer content in LDL(−) contributes 
to both LDL(–)-induced inflammatory and apoptotic effects, whereas Sph plays a more important 
role in its inflammatory effect. By contrast, S1P counteracts the apoptotic action exerted by LDL(–). 
These findings are summarized in Figure 9, which shows the effect of the inhibitors used in the study 
on sphingolipid generation and the ensuing LDL(–)-induced inflammatory and apoptotic actions.  
The increased Cer content in LDL(−) was previously determined by thin layer chromatography, 
which is a much less sensitive method [22]. The current study corroborated this observation and also 
showed a higher content of Sph in LDL(−) compared to LDL(+). On the other hand, we found 
undetectable basal levels of S1P in both LDL fractions. Other authors have detected very low levels 
of S1P in LDL [21,36]. According to Hammad et al., the distribution of S1P in plasma lipoproteins 
was of 94.94% in HDL and only 3.73% in LDL. Compared to that study, the absence of S1P in our 
LDL subfractions could be due to different experimental conditions, such as the range of isolation of 
LDL and the lower concentration of the sample. 
The inflammatory action of LDL(−) on monocytes was reported to be promoted, in part, by its 
increased content in NEFA and Cer [22,27]. The increased Cer content was proposed to be generated 
by the SMase activity ascribed to LDL(−) [22]. This hypothesis is supported by the current data, with 
the use of the SMase inhibitor CPZ, which inhibits the cytokine release promoted by LDL(−) in 
monocytes. Since CPZ blocks the degradation of sphingomyelin to yield Cer, it probably also blocks 
the generation of sphingolipids derived from Cer hydrolysis. In fact, CPZ was the inhibitor that 
promoted the greatest decrease in inflammation and apoptosis. The effect of CPZ was greater in co-
Figure 9. Effect of the inhibitors used in the study on sphingolipid generation and on LDL(−)-induced
inflammatory and apoptotic actions. CPZ blocks sphingomyelin degradation, thereby decreasing Cer
content and LDL(−)-induced cytokine release and apoptosis. MAPP blocks Cer degradation, leading to
a decrease in Sph and NEFA generation, which seems to develop an essential role in inflammation, but
a likely minor role in apoptosis. DMS blocks sphingosine-1-phosphate (S1P) generation, thus leading
to an increase in the apoptotic effect of LDL(−).
The increased Cer content in LDL(−) was previously determined by thin layer chromatography,
which is a much less sensitive method [22]. The current study corroborated this observation and
also showed a higher cont nt of Sph in LDL(−) compare to LDL(+). On the other hand, we found
undetectable basal l vels of S1P in both LDL fractions. Other authors have det cted very low levels of
S1P in LDL [21,39]. Accord ng to Hammad et al., the distributi n of S1P in plasma lipopro ins was
of 94.94% in HDL and only 3.73% in LDL. C mpar d to tha study, the absence of S1P in our LDL
subfractions could be due to different experimental conditions, such as the range of isolation of LDL
and the ower centration of the sample.
T e inflammatory action of LDL(−) on m nocytes was reported to be promoted, in part, by its
increased content in NEFA and Cer [22,28]. The in reased Cer content was proposed to b generated by
the SMase activity ascribed to LDL(−) [22]. This hypothe is is supported by the current ata, with the
use of the SMase inhibitor CPZ, w ich inhibits the cytokine release promoted by LDL(−) in mon cytes.
Since CPZ blocks the degradatio of sphingomyelin to yiel C , it probably also blocks the generation
of sp ingolipids d rived from Cer y rolysis. In fact, CPZ was the inhibitor that promoted the greatest
decrease in inflammatio and a optosis. The effect of CPZ was greater in co-incubatio experime ts
with monocytes and LDL(−) added simultaneously, thereby suggesting that CPZ ould block not only
the intr sic SMase activity in LDL(−), but also cell enzymatic activity.
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The role of Sph in inflammation is largely unknown, although it has been reported that it induces
inflammasome activation, leading to IL-1β induction in macrophages [8]. The current study shows that
Sph contributes to LDL(−)-induced inflammation in monocytes. This is suggested by the inhibition
exerted by MAPP on the cytokine release promoted by LDL(−). However, MAPP is a CDase inhibitor,
which hinders Sph and NEFA generation; thus, its inhibitory effect could also be partly promoted by
decreasing NEFA. The inflammatory role of Sph was also suggested by the effect promoted by Sph-LDL.
LDL(+), modified to increase its Sph content 1.5-fold, promoted cytokine release to a similar extent to
that promoted by LDL(−). Notably, this artificial enrichment was similar to the increased content of
Sph found in LDL(−). The higher Sph content in LDL(−) seems to be generated by a CDase-like activity,
the origin of which could be cells or LDL(−) itself. The latter is suggested by the lack of difference on
LDL(−)-induced cytokine release between pre-incubation and co-incubation with MAPP.
S1P can display both pro-inflammatory and anti-inflammatory effects, depending on the S1P
receptor subtype expressed on cells [40]. However, LDL(−) did not exhibit an increased content in S1P,
and DMS did not inhibit LDL(−)-induced cytokine release in monocytes. Therefore, our results reject
the involvement of S1P in LDL(−)-induced inflammation.
LDL(−) exerts an apoptotic effect in endothelial cells [41,42] and macrophages [29], but its
effect on monocytes had not yet been determined. Some observations made it feasible, because in
this cell type, LDL(−) induces molecules related to apoptosis, such as caspase-1 [36], Fas [43], and
p38 mitogen-activated protein kinase [38]. Regarding other modified LDLs, oxidized LDL exerts a
pro-apoptotic effect in macrophages [31,44]. In monocytes, oxidized LDL can promote both pro-apoptotic
and anti-apoptotic effects [45,46], and enzimatically modified LDL promotes apoptosis [47]. In the
current study, LDL(−) exerted a slight apoptotic action on monocytes, which is rather lower than its
effect found previously on endothelial cells. This could be because the studies of endothelial cells
were performed with L5, which only includes the most negative subfraction of LDL(−), and because
the highest number of apoptotic cells (more than 40%) was only found when L5 was isolated from
dyslipidemic patients [41,48,49]. By contrast, when it was isolated from control subjects, apoptosis
was lower than 10% [41], which is a similar value to that found in the current study. In addition, in
endothelial cells, the effect was mediated through lectin-like oxidized low-density lipoprotein receptor-1
which is a receptor that is barely expressed in monocytes. The induction of apoptosis could lead to
different consequences, depending on the cell type, which is considered to have a pro-atherogenic effect
in endothelial cells, whereas in monocytes, it could be hypothesized that it is a physiological control
mechanism to decrease the accumulation of inflammatory cells.
Some molecules whose concentration is increased in LDL(−), such as LPC, Cer, and NEFA [22,50],
have been shown to be involved in apoptosis [2,32,51]. The results of the current study strongly suggest
that Cer content is mainly responsible for the apoptosis promoted by LDL(−) on monocytes, which
is in agreement with that reported for endothelial cells [30]. First, the inhibition of SMase activity
decreased LDL(−)-induced apoptotic activity on monocytes to an extent similar to that promoted by
LDL(+); second, an increased Cer concentration in LDL(+), which was promoted by SMase treatment,
induced apoptosis on monocytes at the same level as that promoted by LDL(−).
It has been reported that Sph is able to exert apoptotic effects [9,10]. In our experiments, Sph was
not involved in the apoptotic effect promoted by LDL(−). This fact could be explained by the overlapping
biological effects promoted by MAPP, altering the balance between pro-apoptotic and anti-apoptotic
molecules owing to CDase inhibition, because MAPP may exert both an anti-apoptotic effect by
decreasing Sph and NEFA content, and an apoptotic effect by increasing Cer content. However, the
inhibition of S1P formation by the addition of DMS to monocytes increased LDL(−)-induced apoptosis.
This observation is in agreement with the assertion that S1P has anti-apoptotic effects [14].
In summary, our data showed that the increased Cer content in LDL(−) contributed to its
inflammatory and apoptotic effects on monocytes. Sph played a key role in inflammation, and S1P
counteracted the apoptotic effect of LDL(−). The main limitation of our study is that it is an “in vitro”
approximation, and it is difficult to evaluate the effect of the different sphingolipids separately, owing
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to the complexity of their metabolism and their interconversion. In addition, other factors remain
to be examined in future studies, including the presence of enzymatic activities in LDL(−), yielding
its increased content in Sph, and the content of this bioactive sphingolipid through incubation with
monocytes in the presence or absence of enzyme inhibitors.
5. Conclusions
The current study provides new knowledge regarding the role of sphingolipids in mediating
LDL(−)-induced inflammatory and apoptotic effects in monocytes. Our data suggest that the increased
Cer content in LDL(−) contributes to both effects. Not only Cer, but also its hydrolysis product Sph,
seems to play a key role in inflammation, and S1P counteracts the apoptotic effect of LDL(−).
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/9/8/300/s1,
Figure S1: Modification of LDL by Sph enrichment and SMase treatment, Table S1: Apoptosis (% apoptotic cells)
induced in the absence (blank) or presence of inhibitors at 10 µM (n = 5), * vs. blank, p < 0.05.
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